MedTech Leaders to Examine AI's Bottom-Line Impact in May Webinar
Medical device companies will hear from acquisition specialists about whether AI is actually creating value in their business operations. MedWorld Advisors is hosting a free webinar on May 13 at 12 p.m. ET called "The Value of AI in MedTech - from Start-Up to Operational Excellence to M&A."
The session targets medtech companies at different growth stages: startups, scaling operations, and those preparing for exit. Speakers will address how AI affects valuation and deal outcomes.
Who's Speaking
Daniel Sheppard, managing director at MedWorld Advisors, has spent nearly two decades on M&A and corporate finance work for medtech and healthcare finance firms. He joined MedWorld in 2016 and manages deal processes, applying financial and project management experience to maximize value creation in transactions.
Dave Sheppard, also a managing director at MedWorld Advisors, has led the medical device industry for more than 30 years. His background includes general manager and VP roles at Fortune 500 companies including Medtronic, BD, and Cooper, plus startup experience with a pre-IPO company that went public.
Sheppard has completed cross-border deals and holds a global network of contacts across major healthcare manufacturers and smaller channel partners. His experience spans distribution, licensing, and M&A work with companies like GE, Philips, and Stryker.
Why This Matters for Management
For managers evaluating AI investments, the webinar offers perspective from advisors who work directly with companies during acquisitions and strategic exits. Understanding AI's actual value impact - not just the marketing claims - affects investment decisions and company valuation.
Managers responsible for operational decisions can learn how AI affects efficiency and profitability across different company sizes and business models.
Learn more about AI for executives and strategy to deepen your understanding of how AI creates business value.
Your membership also unlocks:
